SMO and pancreatic neoplasm: This led to a clinical trial of the small molecular SMO inhibitor, IPI-926 (Infinity Pharmaceuticals), and parallel trials of a separate SMO inhibitor, GDC-0449 (vismodegib, Genentech) in patients with pancreatic cancer.